Eileen Boyle, MD, PhD, NYU Langone, New York, NY, comments on interactions between the tumor and the microenvironment in multiple myeloma and how these can impact patients’ response to therapy and increase the likelihood to develop treatment-related complications. A recent study has shown that the presence of NK cells and monocytes in the microenvironment was associated with poor response to treatment. According to Dr Boyle, manipulating the immune microenvironment using available therapies in a patient-specific targeted approach could help improve patient outcomes, especially in those with high-risk disease. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.